NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Price Target & More

$4.23 -0.04 (-0.94 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$4.27
Today's Range$4.20 - $4.30
52-Week Range$3.00 - $5.10
Volume45,205 shs
Average Volume167,862 shs
Market Capitalization$240.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73

About Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical logoNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Debt-to-Equity RatioN/A
Current Ratio0.43%
Quick Ratio0.43%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$220,000.00
Price / Sales1,099.99
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-211.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-13,420,000.00
Net Margins-5,901.09%
Return on EquityN/A
Return on Assets-927.74%

Miscellaneous

Employees6
Outstanding Shares57,210,000

How to Become a New Pot Stock Millionaire

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical (NASDAQ:NYMX) announced its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. View Nymox Pharmaceutical's Earnings History.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Nymox Pharmaceutical.

Who are some of Nymox Pharmaceutical's key competitors?

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the folowing people:
  • Dr. Paul Averback M.D., DABP, Founder, Chairman, CEO & Pres (Age 67)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 55)
  • Mr. Randall J. Lanham Esq., Gen. Counsel, Sec. & Director (Age 54)
  • Dr. Judith Fitzpatrick Ph.D., Exec. (Age 69)
  • Dr. Suresh Kalbag M.D., Director of CMC Operations

Has Nymox Pharmaceutical been receiving favorable news coverage?

Headlines about NYMX stock have trended somewhat positive on Wednesday, according to Accern. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $4.23.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $240.27 million and generates $220,000.00 in revenue each year. Nymox Pharmaceutical employs 6 workers across the globe.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, St.-Laurent A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical (NYMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nymox Pharmaceutical (NASDAQ:NYMX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Nymox Pharmaceutical (NASDAQ:NYMX) Earnings History and Estimates Chart

Earnings by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
8/7/2017Q2 2017($0.05)$0.01 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.06)$0.08 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.06)$0.04 millionViewN/AView Earnings Details
11/15/2016Q3 2016($0.07)$0.05 millionViewN/AView Earnings Details
8/22/2016Q2 2016($0.08)$0.15 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.07)$0.04 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.10)$0.08 millionViewN/AView Earnings Details
12/31/2015Q3 2015($0.26)$0.05 millionViewN/AView Earnings Details
8/24/2015Q2 2015($0.63)$0.06 millionViewN/AView Earnings Details
5/15/2015Q1 2015$0.04$0.08 millionViewN/AView Earnings Details
3/31/2015Q4 2014($0.01)$0.08 millionViewN/AView Earnings Details
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.02)$0.10 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.07)$0.08 millionViewN/AView Earnings Details
3/14/2014Q4 2013($0.03)$0.94 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)$0.74 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.04)$0.19 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.1843 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.05)($0.08)ViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.06)($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.06)($0.06)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.06)($0.06)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.05)($0.05)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.04)($0.06)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.05)($0.14)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.05)($0.07)ViewN/AView Earnings Details
11/12/2010Q3 2010($0.05)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.05)ViewN/AView Earnings Details
5/14/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.05)ViewN/AView Earnings Details
11/13/2009Q3 2009($0.04)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.04)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.03)ViewN/AView Earnings Details
11/14/2008Q3 2008($0.05)ViewN/AView Earnings Details
8/13/2008Q2 2008($0.04)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.04)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Nymox Pharmaceutical (NASDAQ:NYMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 6.26%
Insider Trading History for Nymox Pharmaceutical (NASDAQ:NYMX)
Institutional Ownership by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2018James George RobinsonDirectorBuy8,000$3.93$31,440.003,159,550View SEC Filing  
3/20/2018James George RobinsonDirectorBuy8,000$4.02$32,160.003,152,550View SEC Filing  
3/15/2018James George RobinsonDirectorBuy8,000$3.58$28,640.003,144,550View SEC Filing  
3/9/2018James George RobinsonDirectorBuy8,000$3.48$27,840.003,136,550View SEC Filing  
2/21/2018James George RobinsonDirectorBuy6,000$3.23$19,380.003,123,250View SEC Filing  
2/16/2018James George RobinsonDirectorBuy7,000$3.27$22,890.00View SEC Filing  
2/12/2018James George RobinsonDirectorBuy8,000$3.27$26,160.003,107,850View SEC Filing  
2/8/2018James George RobinsonDirectorBuy10,000$3.37$33,700.003,091,050View SEC Filing  
2/2/2018James George RobinsonDirectorBuy5,000$3.47$17,350.003,090,550View SEC Filing  
1/18/2018James George RobinsonDirectorBuy3,000$3.14$9,420.003,085,550View SEC Filing  
8/3/2017James George RobinsonDirectorBuy10,000$3.73$37,300.003,077,550View SEC Filing  
8/2/2017James George RobinsonDirectorBuy5,000$3.79$18,950.003,077,550View SEC Filing  
8/1/2017James George RobinsonDirectorBuy15,000$3.72$55,800.003,062,550View SEC Filing  
7/7/2017James George RobinsonDirectorBuy11,500$4.00$46,000.003,046,550View SEC Filing  
7/6/2017James George RobinsonDirectorBuy3,000$3.92$11,760.003,046,550View SEC Filing  
7/5/2017James George RobinsonDirectorBuy5,000$3.97$19,850.003,046,550View SEC Filing  
6/28/2017James George RobinsonDirectorBuy8,500$4.09$34,765.003,040,050View SEC Filing  
6/26/2017James George RobinsonDirectorBuy15,000$3.80$57,000.003,027,550View SEC Filing  
6/21/2017James George RobinsonDirectorBuy15,000$3.77$56,550.003,008,150View SEC Filing  
6/20/2017James George RobinsonDirectorBuy5,000$3.76$18,800.003,008,150View SEC Filing  
6/19/2017James George RobinsonDirectorBuy5,000$3.79$18,950.003,008,150View SEC Filing  
5/30/2017James George RobinsonDirectorBuy54,500$3.81$207,645.002,957,550View SEC Filing  
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.002,906,078View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.002,907,550View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.002,902,550View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.002,880,050View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.002,870,050View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.002,850,050View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.002,833,050View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.002,810,050View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.102,782,550View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.402,777,050View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.002,762,550View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.002,722,550View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.002,701,050View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.002,659,050View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.002,657,550View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.002,637,550View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.002,542,550View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.002,542,550View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.002,542,550View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.162,517,550View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.042,487,696View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.122,424,362View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.002,377,550View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.002,267,550View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nymox Pharmaceutical (NASDAQ NYMX) News Headlines

Source:
DateHeadline
Analyzing Nymox Pharmaceutical (NYMX) and Quotient (QTNT)Analyzing Nymox Pharmaceutical (NYMX) and Quotient (QTNT)
www.americanbankingnews.com - April 23 at 9:20 PM
Quidel (QDEL) versus Nymox Pharmaceutical (NYMX) Head-To-Head AnalysisQuidel (QDEL) versus Nymox Pharmaceutical (NYMX) Head-To-Head Analysis
www.americanbankingnews.com - April 23 at 1:28 PM
Head to Head Survey: Celldex Therapeutics (CLDX) and Nymox Pharmaceutical (NYMX)Head to Head Survey: Celldex Therapeutics (CLDX) and Nymox Pharmaceutical (NYMX)
www.americanbankingnews.com - April 20 at 3:34 PM
Nymox Pharmaceutical (NYMX) Cut to Sell at ValuEngineNymox Pharmaceutical (NYMX) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 20 at 1:19 PM
Nymox Pharmaceutical (NYMX) Stock Rating Lowered by ValuEngineNymox Pharmaceutical (NYMX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Analyzing BG Medicine (BGMD) and Nymox Pharmaceutical (NYMX)Analyzing BG Medicine (BGMD) and Nymox Pharmaceutical (NYMX)
www.americanbankingnews.com - April 16 at 9:27 AM
Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?
finance.yahoo.com - April 14 at 9:37 AM
Nymox secures $16.25M capital raiseNymox secures $16.25M capital raise
seekingalpha.com - April 12 at 4:26 PM
Nymox Pharma (NYMX) Reports $16.25 Million Equity Financing With Qualified Long-Term InvestorsNymox Pharma (NYMX) Reports $16.25 Million Equity Financing With Qualified Long-Term Investors
www.streetinsider.com - April 12 at 4:26 PM
Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term InvestorsNymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors
finance.yahoo.com - April 12 at 10:22 AM
Nymox Pharmaceutical (NYMX) Upgraded at ValuEngineNymox Pharmaceutical (NYMX) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of UrologyNew Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
finance.yahoo.com - April 10 at 4:27 PM
Contrasting Nymox Pharmaceutical (NYMX) & Immunomedics (IMMU)Contrasting Nymox Pharmaceutical (NYMX) & Immunomedics (IMMU)
www.americanbankingnews.com - April 4 at 11:20 AM
Nymox Pharmaceutical (NYMX) vs. Lantheus (LNTH) Critical ReviewNymox Pharmaceutical (NYMX) vs. Lantheus (LNTH) Critical Review
www.americanbankingnews.com - April 3 at 7:17 PM
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Acquires 8,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Acquires 8,000 Shares
www.americanbankingnews.com - March 27 at 10:50 PM
James George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) StockJames George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock
www.americanbankingnews.com - March 22 at 8:13 PM
Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?
finance.yahoo.com - March 19 at 4:20 PM
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 8,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 8,000 Shares
www.americanbankingnews.com - March 16 at 1:55 PM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
finance.yahoo.com - March 1 at 4:48 PM
Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks LikeInterested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 28 at 9:25 AM
James George Robinson Purchases 6,000 Shares of Nymox Pharmaceutical Co. (NYMX) StockJames George Robinson Purchases 6,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock
www.americanbankingnews.com - February 23 at 12:50 PM
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 7,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 7,000 Shares
www.americanbankingnews.com - February 20 at 7:50 PM
Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 10,000 SharesNymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 10,000 Shares
www.americanbankingnews.com - February 9 at 6:34 PM
Nymox Pharmaceutical Co. (NYMX) Director Acquires $17,350.00 in StockNymox Pharmaceutical Co. (NYMX) Director Acquires $17,350.00 in Stock
www.americanbankingnews.com - February 6 at 7:00 PM
Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)
globenewswire.com - February 6 at 9:06 AM
Nymox Announces US NDA for Fexapotide for BPHNymox Announces US NDA for Fexapotide for BPH
finance.yahoo.com - February 5 at 4:25 PM
The Clock Is Ticking For Nymox Pharmas European Drug Application - Bet On A Rejection - Seeking AlphaThe Clock Is Ticking For Nymox Pharma's European Drug Application - Bet On A Rejection - Seeking Alpha
seekingalpha.com - February 2 at 9:08 AM
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of UrologyFexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
finance.yahoo.com - January 30 at 9:33 AM
Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. MenNymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
www.streetinsider.com - January 23 at 4:06 PM
Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study ... - StreetInsider.comNymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study ... - StreetInsider.com
www.streetinsider.com - January 23 at 8:19 AM
AMGNs LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - NasdaqAMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - Nasdaq
www.nasdaq.com - January 23 at 8:19 AM
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. MenNymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
finance.yahoo.com - January 22 at 5:50 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017
finance.yahoo.com - December 22 at 7:31 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:44 PM
ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017
finance.yahoo.com - November 30 at 4:34 PM
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:25 AM
Nymox Fexapotide Symposium and Panel Discussion at American ... - GlobeNewswire (press release)Nymox Fexapotide Symposium and Panel Discussion at American ... - GlobeNewswire (press release)
globenewswire.com - November 27 at 4:43 PM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological AssociationSymposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association
www.nasdaq.com - November 12 at 11:14 AM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological Association North ...Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North ...
globenewswire.com - November 12 at 11:14 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - NasdaqNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - Nasdaq
www.nasdaq.com - November 9 at 7:56 AM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ...
globenewswire.com - November 7 at 4:34 PM
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in HavanaNymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
finance.yahoo.com - November 7 at 4:34 PM
Notable Wednesday Option Activity: ULTI, NYMX, XPO - NasdaqNotable Wednesday Option Activity: ULTI, NYMX, XPO - Nasdaq
www.nasdaq.com - November 2 at 7:11 AM
Nymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in OctoberNymox Pharmaceutical Corporation (NYMX) Short Interest Down 22.8% in October
www.americanbankingnews.com - October 28 at 2:26 AM
Short Interest Drops 22.8% For NYMXShort Interest Drops 22.8% For NYMX
www.thestreet.com - October 27 at 8:53 AM
Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
finance.yahoo.com - October 27 at 8:53 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...
globenewswire.com - October 14 at 6:23 AM
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in SavannahNymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
finance.yahoo.com - October 14 at 6:23 AM
Nymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short InterestNymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 1:40 AM
Short Interest Falls 63.6% For NYMXShort Interest Falls 63.6% For NYMX
www.thestreet.com - October 12 at 7:45 AM

SEC Filings

Nymox Pharmaceutical (NASDAQ:NYMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nymox Pharmaceutical (NASDAQ:NYMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nymox Pharmaceutical (NASDAQ NYMX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.